Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Clin Chem. 2010 May;56(5):714-22. doi: 10.1373/clinchem.2009.133660. Epub 2010 Mar 26.
Accrediting organizations require laboratories to establish analytic performance criteria that ensure their tests provide results of the high quality required for patient care. However, the procedures for instituting performance criteria that are directly linked to the needs of medical practice are not well established, and therefore alternative strategies often are used to create and implement surrogate performance standards.
We reviewed 6 approaches for establishing outcome-related analytic performance goals: (a) limits defined by regulations and external assessment programs, (b) limits based on biologic variation, (c) limits based on surveys of clinicians about their needs, (d) limits based on effects on guideline driven medical decisions, (e) limits based on analysis of patterns for ordering follow-up clinical tests, and (f) limits based on formal medical decision models. Performance criteria were tabulated for 12 common chemistry analytes and 4 routine hematology tests.
There is no consensus currently about the preferred methods for establishing medically necessary analytic performance limits. The various methods reviewed give considerably different performance limits. The analytic performance limits claimed by a laboratory should correspond to those limits that can be reliably maintained based on validated QC monitoring systems. These limits generally are larger than the observed CVs and bias parameters collected for assay validation. There is a major need for increased communication among laboratorians and clinicians on this topic, especially when the analytic performance limits that can be consistently maintained by a laboratory are inconsistent with the expectations of health care providers.
认证机构要求实验室建立分析性能标准,以确保其测试结果能够满足患者护理所需的高质量要求。然而,与医疗实践需求直接相关的性能标准的制定程序尚未得到很好的确立,因此通常会采用替代策略来制定和实施替代性能标准。
我们回顾了建立与结果相关的分析性能目标的 6 种方法:(a)法规和外部评估计划定义的限制,(b)基于生物学变异的限制,(c)基于临床医生需求调查的限制,(d)基于对指南驱动的医学决策影响的限制,(e)基于分析后续临床测试订单模式的限制,以及(f)基于正式医学决策模型的限制。为 12 种常见化学分析物和 4 种常规血液学测试制定了性能标准。
目前对于建立医学上必需的分析性能限制的首选方法尚未达成共识。所审查的各种方法给出了相当不同的性能限制。实验室声称的分析性能限制应与基于经过验证的 QC 监测系统可靠维持的那些限制相对应。这些限制通常比为验证收集的观察到的 CV 和偏倚参数大。在这个主题上,实验室人员和临床医生之间需要增加沟通,尤其是当实验室能够持续维持的分析性能限制与医疗保健提供者的期望不一致时。